Compare H2O America (HTO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Neurocrine Biosciences Inc — how do they compare? H2O America trades at $58.48 (market cap $2.43B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.9× H2O America's market cap, and H2O America pays a 3.03% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HTO | NBIX | |
|---|---|---|
Market Cap | $2.43B | $14.36B |
Volume | 593,883 | 1,237,180 |
Sector | Utilities | Health |
52-Week High | $65.43 | $185.50 |
52-Week Low | $44.44 | $123.10 |
Typical Hold Time | 40 Days | 23 Days |
Enterprise Value | $4.22B | $14.37B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.07, up 0.16% with a bearish technical signal despite bullish oscillators. The company shows solid fundamentals with 12.91% net income margin and recent earnings beats in Q1 and Q2 2026. Recent acquisitions in Texas signal growth ambitions, though cash flow trends show heavy investing activity. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target.
The stock offers potential upside to analyst targets but faces execution risks from recent acquisitions and dilution concerns. Strong institutional interest from BlackRock and others supports the growth story, though technical weakness and high investing cash outflows warrant monitoring. The Dividend King status provides income stability amid expansion efforts.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
